Drugs / GSK249320
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00833989 | Jul 2009 → Jan 2011 | transient ischemic attack | GlaxoSmithKline | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01808261 Comparator | May 2013 → Jul 2014 | cerebral infarction | GlaxoSmithKline | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK249320 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00833989 ↗ |
| Action | Inhibit | “antagonises or neutralises MAG-mediated inhibition” NCT00833989 ↗ |
| Modality | Monoclonal antibody | “GSK249320 is a humanised monoclonal antibody (mAb)” NCT00833989 ↗ |
| Route | Intravenous | “I.V. infusion” NCT00833989 ↗ |
| Target | MAG | “binds with high specificity to myelin-associated glycoprotein (MAG)” NCT00833989 ↗ |